Respiratory syncytial virus (RSV), associated with bronchiolitis and asthma, is resistant to the antiviral effects of type-I interferons (IFN), but not IFN-␥. However, the antiviral mechanism of IFN-␥ action against RSV infection is unknown. The molecular mechanism of IFN-␥-induced antiviral activity was examined in this study using human epithelial cell lines HEp-2 and A549. Exposure of these cells to 100 -1000 units/ml of IFN-␥, either before or after RSV infection, results in a significant decrease in RSV infection.
The respiratory syncytial virus (RSV)1 is the most important cause of lower respiratory tract infection in infants and young children worldwide and is a risk factor for the development of asthma. In the United States alone, RSV causes ϳ4 million cases of respiratory tract infection annually, which results in 95,000 hospitalizations and 4,500 deaths (1, 2). An effective prophylaxis or treatment against RSV is not available. Intranasal administration of a plasmid expressing IFN-␥ cDNA or a recombinant RSV expressing IFN-␥ attenuates virus replication in mice without compromising immunogenicity (3, 4). The potential and mechanism of IFN-␥ as an antiviral agent against RSV-induced lung disease remain to be elucidated.IFN-␥, a type II interferon, is a pleiotropic cytokine that plays an important role in modulating nearly all phases of immune and inflammatory responses. IFNs bind to specific receptors on cells and activate a JAK-STAT (Janus kinasesignal transducer and activator of transcription) signaling cascade that culminates in the transcriptional induction of IFNstimulated genes (ISGs) (5). The Jak1 and Jak2 phosphorylate STAT-1 following the binding of IFN-␥ to its receptor (5-7). Once phosphorylated, STAT molecules dimerize and translocate to the nucleus and bind to ␥-activated sequence elements present in the regulatory regions of various ISGs. The antiviral mechanism of IFN-␥ may involve one or more of a number of ISG-encoded products, including interferon regulatory factor-1 (IRF-1) (8), double-stranded RNA-activated protein kinase (PKR) (9, 10), the Mx family of proteins (11), a family of 2Ј-5Ј oligoadenylate synthetases (2-5 AS) (12, 13), and RNase L (14).The RNase L is constitutively expressed in most of the mammalian cells and is found in an inactive form being bound to RNase L inhibitor, RLI, a 68-kDa protein not regulated by IFN-␥ (15). The 2-5 AS produces a series of 5Ј-phosphorylated and 2Ј-and 5Ј-linked oligoadenylates (2-5A) from ATP when activated by double-stranded RNA (12, 16). It has been suggested that the binding of 2-5A with RNase L results in the release of RLI, dimerization, and the activation of RNase L (17), and subsequently activated RNase L mediates the cleavage of single-stranded RNA. However, the mechanism of the induction and activation of each of these genes vary in different cells and for the type of viruses. The mechanism of the IFN-␥-mediated antiviral activity remains to be elucidated for many clinically important viruses.Previously, we have shown that in BALB/c...